Tamoxifen: Important considerations of a multi-functional compound with organ-specific properties

Cancer Treatment Reviews

Volumn 33, Issue 2, 2007, Pages 91-100

  Singh, Maneesh N ^a,b   Stringfellow, Helen F ^a   Paraskevaidis, Evangelos ^c   Martin Hirsch, Pierre L ^a   Martin, Francis L ^b  

^a LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Endometrioid endometrial carcinoma; Genotoxicity; Malignant mixed mullerian tumour; Non genotoxic; Oestrogen receptor; SERM; Serous papillary endometrial carcinoma; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CLOMIFENE CITRATE; CYCLOOXYGENASE 1; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; K RAS PROTEIN; LETROZOLE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN B; TAMOXIFEN; TOREMIFENE; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR SNAIL;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; BODY MASS; BREAST CANCER; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA ADDUCT; DNA DAMAGE; DRUG RESEARCH; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ENDOMETRIUM SARCOMA; FRAGILITY FRACTURE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTOXICITY; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LIVER CANCER; MIXED MULLERIAN TUMOR; NONHUMAN; NULLIPARA; OVARY POLYCYSTIC DISEASE; OVERALL SURVIVAL; OVULATION INDUCTION; PATHOPHYSIOLOGY; PLEIOTROPY; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TISSUE SPECIFICITY; TREATMENT DURATION; UTERUS DISEASE; VAGINA BLEEDING;

BREAST NEOPLASMS; FEMALE; HUMANS; ORGAN SPECIFICITY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33847292423     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.09.008     Document Type: Review

References (141)

1. Powles T.J. Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol 24 (1997) S1-48-S1-54
2. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
3. Fisher B., Constantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
4. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 36 (2003) 296-300
5. Early Breast Cancer Trialists' Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
6. Curtis R.E., Boice Jr. J.D., Shriner D.A., Hankey B.F., and Fraumeni Jr. J.F. Second cancers after the adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88 (1996) 832-834
7. Fisher B., Constantino J.P., Redmond C.K., Wickerman D.L., and Cronin W.M. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (1994) 527-537
8. Rutqvist L.E., Johansson H., Signomklao T., et al. Sockholm breast cancer study group. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87 (1995) 645-651
9. van Leeuwen F.E., Benraadt J., Coebergh J.W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452
10. IARC on tamoxifen. Environ Health Perspect 1996;104:688.
11. Pole J.C.M., Gold L.I., Orton T., Huby R., and Carmichael P.L. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen. Toxicology 206 (2005) 91-109
12. The breast international group (BIG) 1-98 Collaborative group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
13. Love R.B., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 (1992) 852-856
14. Eastell R., Hannon R.A., Cuzick J., et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2 year results of Anastrozole, Tamoxifen, alone or in combination (ATAC) trial. J Bone Miner Res 21 (2006) 1215-1223
15. Chang J., Powles T.J., Ashley S.E., et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7 (1996) 671-675
16. Herrington D.M., and Klein K.P. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 11 (2001) 95-102
17. Bradbury B.D., Lash T.L., Kaye J.A., and Jick S.S. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 103 (2005) 1114-1121
18. Rutqvist L.E., and Mattsson A. Cardiac and thromboembolic morbidity among post-menopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm breast cancer study group. J Natl Cancer Inst 85 (1993) 1398-1406
19. McDonald C.C., Alexander F.E., Whyte B.W., Forrest A.P., and Stewart H.J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish cancer trials breast group. BMJ 311 (1995) 977-980
20. Reis S.E., Costantino J.P., Wickerham D.L., et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 93 (2001) 16-21
21. Steiner A.Z., Terplan M., and Paulson R.J. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Human Reprod 20 (2005) 1511-1515
22. Sonmezer M., and Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 11 (2006) 422-434
23. Neven P., and Vergote I. Tamoxifen, screening and new oestrogen receptor modulators. Best Pract Res Clin Obstet Gynaecol 15 (2001) 365-380
24. Vosse M., Renard F., Coibion M., et al. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 101 (2002) 58-63
25. Ismail S.M. The effects of tamoxifen on the uterus. Curr Opin Obstet Gynecol 8 (1996) 27-31
26. Kedar R.P., Bourne T.H., Powles T.J., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343 (1994) 1318-1321
27. Nevan P., and Vergote I. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 22 (2000) 1-11
28. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 29 (2006) 2727-2741
29. Veronesi U., Boyle P., Goldhirsch A., Orrechia R., and Viale G. Breast cancer. Lancet 365 (2005) 1727-1741
30. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281 (1999) 2189-2197
31. Jordan V.C., Lewis J.S., Osipo C., and Cheng D. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast 14 (2005) 624-630
32. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Clinical considerations and new agents. J Med Chem 46 (2003) 1081-1128
33. Sato M., Turner C.H., Wang T., et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287 (1998) 1-7
34. Munster P.N., Buzdar A., Dhingra K., et al. Phase 1 study of a third generation selective oestrogen receptor modulator, LY353381.HCl, in metastatic breast cancer. J Clin Oncol 19 (2001) 2002-2009
35. Gutman M., Couillard S., Roy J., et al. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumours in nude mice. Int J Cancer 99 (2002) 273-278
36. Brady H., Doubleday M., Gayo-Fung L.M., et al. Differential response of estrogen receptors α and β to SP500263, a novel potent selective estrogen receptor modulator. Mol Pharmacol 61 (2002) 562-568
37. Lissoni P., Vigano P., Vaghi M., et al. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Anticancer Res 25 (2005) 3597-3599
38. Takase Y., Levesque M.H., Luu-The V., et al. Expression of enzymes involved in estrogen metabolism in human prostate. J Histochem Cytochem 54 (2006) 911-921
39. Ragavan N., Hewitt R., Cooper L.J., et al. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett 215 (2004) 69-78
40. Lippman S.M., and Lee J.J. Reducing the "risk" of chemoprevention: defining and targeting high risk - 2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66 (2006) 2893-2903
41. Han X., and Liehr J.G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52 (1992) 1360-1363
42. Osborne M.R., Hewer A., Hardcastle I.R., Carmichael P.L., and Phillips D.H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 56 (1996) 66-71
43. Tannenbaum S.R. Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin Oncol 24 (1997) S1-6-S1-8
44. Williams G.M., Iatropoulos M.J., Djordjevic M.V., and Kaltenberg O.P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14 (1993) 315-317
45. Greaves P., Goonetilleke R., Nunn G., Topham J., and Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53 (1993) 3919-3924
46. Davis W., Hewer A., Rajkowski K.M., et al. Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and rat hepatocytes in vitro: role of sulphotransferase induction. Cancer Res 60 (2000) 2887-2891
47. Phillips D.H. Understanding the genotoxicity of tamoxifen?. Carcinogenesis 22 (2001) 839-849
48. Boocock D.J., Brown K., Gibbs A.H., et al. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23 (2002) 1897-1901
49. Osborne M.R., Davis W., Hewer A.J., Hardcastle I.R., and Phillips D.H. 4-hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells. Chem Res Toxicol 12 (1999) 151-158
50. Phillips D.H., Hewer A., Horton M.N., et al. N-Demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis 20 (1999) 2003-2009
51. Sharma M., Shubert D.E., Sharma M., et al. Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact 146 (2003) 237-249
52. Phillips D.H., Hewer A., Osborne M.R., et al. Organ specificity of DNA adduct formation by tamoxifen and α-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment. Mutagenesis 20 (2005) 297-303
53. Apak T.I., and Duffel M.W. Interactions of the stereoisomers of α-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug Metab Dispos 32 (2004) 1501-1508
54. Davis W., Venitt S., and Phillips D.H. The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis 19 (1998) 861-866
55. Glatt H., Davis W., Meinl W., et al. Rat, but not human, sulphotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 19 (1998) 1709-1713
56. Shibutani S., Suzuki N., Terashima I., et al. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol 12 (1999) 646-653
57. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59 (1999) 2091-2095
58. Kim S.Y., Suzuki N., Laxmi Y.R., et al. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to α-hydroxytamoxifen. Chem Res Toxicol 18 (2005) 889-895
59. Martin E.A., Brown K., Gaskell M., et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 63 (2003) 8461-8465
60. Carmichael P.L., Ugwumadu A.H., Neven P., et al. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56 (1996) 1475-1479
61. 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20 (1999) 339-342
62. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J Natl Cancer Inst 96 (2004) 1099-1104
63. 32P-postlabeling. Biochem Biophys Res Commun 320 (2004) 297-302
64. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
65. Nilsson S., Makela S., Treuter E., et al. Mechanisms of estrogen action. Physiol Rev 81 (2001) 1535-1565
66. Yamamoto Y., Wada O., Suzawa M., et al. The tamoxifen-responsive estrogen receptor α mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. J Biol Chem 276 (2001) 42685-42691
67. Pearce S.T., Liu H., and Jordan V.C. Modulation of estrogen receptor α function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem 278 (2003) 7630-7638
68. Koehler K.F., Helguero L.A., Haldosen L., Warner M., and Gustafsson J. Reflections on the discovery and significance of estrogen receptor β. Endocrin Rev 26 (2005) 465-478
69. Weihua Z., Makela S., Andersson L.C., et al. A role for estrogen receptor β in the regulation of the ventral prostate. Proc Natl Acad Sci USA 98 (2001) 6330-6335
70. Makinen S., Makela S., Weihua Z., et al. Localisation of oestrogen receptors α and β in human testis. Mol Hum Reprod 7 (2001) 497-503
71. Cheng G., Weihua Z., Makinen S., et al. A role for the androgen receptor in follicular atresia of oestrogen receptor β knockout mouse ovary. Biol Reprod 66 (2002) 77-84
72. Valimaa H., Savolainen S., Soukka T., et al. Estrogen receptor-β is the predominant estrogen receptor subtype in human oral epithelium and salivary glands. J Endocrinol 180 (2004) 55-62
73. Lindner V., Kim S.K., Karas R.H., et al. Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circ Res 83 (1998) 224-229
74. Barchiesi F., Jackson E.K., Imthurn B., et al. Differential regulation of estrogen receptor subtypes α and β in human aortic smooth muscle cells by oligonucleotides and estradiol. J Clin Endocrinol Metab 89 (2004) 2372-2381
75. Shughrue P.J., Scrimo P.J., and Merchenthaler I. Estrogen binding and estrogen receptor characterization (ERα and ERβ) in the cholinergic neurons of the rat basal forebrain. Neuroscience 96 (2000) 41-49
76. Bennett H.L., Gustafsson J.A., and Keast J.R. Estrogen receptor expression in lumbosacral dorsal root ganglion cells innervating the female rat urinary bladder. Auton Neurosci 105 (2003) 90-100
77. Shim G.J., Wang L., Andersson S., et al. Disruption of the estrogen receptor β gene in mice causes myeloproliferative disease resembling chronic myeloid leukaemia with lymphoid blast crisis. Proc Natl Acad Sci USA 100 (2003) 6694-6699
78. Periwal S.B., Farooq A., Bhargava V.L., et al. Effect of hormones and antihormones on phospholipase A2 activity in human endometrial stroma cells. Prostaglandins 51 (1996) 191-201
79. Barakat R.R., Wong G., Curtin J.P., Vlamis V., and Hoskins W.J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55 (1994) 164-168
80. Shen S.S., Smith C.L., Hsieh J.T., et al. Expression of estrogen receptors-α and -β in bladder cell lines and human bladder tumor tissue. Cancer 106 (2006) 2610-2616
81. Clement P.B., and Young R.H. Endometrioid carcinoma of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 9 (2002) 145-184
82. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 (1983) 10-17
83. Zaino R.J., and Kurman R.J. Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma. Semin Diagn Pathol 5 (1988) 154-171
84. Creasman W.T. FIGO stage 1988 revision. Gynecol Oncol 35 (1989) 125-127
85. Zaino R.J., Kurman R.J., Diana K.L., and Morrow C.P. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. Cancer 75 (1995) 81-86
86. Lax S.F., Kurman R.J., Pizer E.S., Wu L., and Ronnett B.M. A binary architectural grading system for uterine endometrial endometrioid carcinoma has the superior reproducibility compared with FIGO grading and identifies subsets of advanced-stage tumours with favourable and unfavourable prognosis. Am J Surg Pathol 24 (2000) 1201-1208
87. Stefansson I.M., Salveson H.B., Immervoll H., and Akslen L.A. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 44 (2004) 472-479
88. Abeler V.M., and Kjorstad K.E. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 31 cases. Cancer 68 (1991) 98-105
89. Hendrickson M.R., Ross J., Eifel P., Martinez A., and Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial cancer. Am J Surg Pathol 6 (1982) 93-108
90. Slomovitz B.M., Burke T.W., Eifel P.J., et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91 (2003) 463-469
91. Carcangiu M.L., and Chambers J.T. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol Oncol 47 (1992) 298-305
92. Wheeler D.T., Bell K.A., Kurman R.J., and Sherman M.E. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 24 (2000) 797-806
93. Ambros R.A., Sherman M.E., Zahn C.M., Bitterman P., and Kurman R.J. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumours displaying serous differentiation. Hum Pathol 26 (1995) 1260-1267
94. Carcangiu M.L., Tam L.K., and Chambers J.T. Stage 1A uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 21 (1997) 1507-1514
95. Soslow R.A., Pirog E., and Isacson C. Endometrial intraepithelial carcinoma associated with peritoneal carcinomatosis. Am J Surg Pathol 24 (2000) 726-732
96. Eifel P., Hendrickson M., Ross J., et al. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer 50 (1982) 163-170
97. Ulbright T.M., and Roth L.M. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 16 (1985) 28-34
98. Ronnett B., Zaino R., Ellenson L., et al. Endometrial carcinoma. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract. 5th ed. (2002), Springer, New York 501-560
99. Fornander T., Rutqvist L.E., Cedermark B., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 (1989) 117-120
100. Andersson M., Storm H.H., and Mouridsen H.T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83 (1991) 1013-1017
101. Sasco A.J., Chaplain G., Amoros E., and Saez S. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 7 (1996) 9-13
102. Curtis R.E., Boice Jr. J.D., Shriner D.A., Hankey B.F., and Fraumeni Jr. J.F. Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst 88 (1996) 832-834
103. Bernstein L., Deapen D., Cerhan J.R., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 99 (1999) 1654-1662
104. Van Leeuwen F.E., Bergman L., and Benraadt J. Does risk of endometrial cancer increase with longer duration of tamoxifen use?. Eur J Cancer 34 suppl 4 (1998) S44-S45
105. Bergman L., Beelen M.L., Gallee M.P., et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356 (2000) 881-887
106. Swerdlow A.J., and Jones M.E. Tamoxifen treatment of breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97 (2005) 375-384
107. Curtis R.E., Freedman D.M., Sherman M.E., and Fraumeni Jr. J.F. Risk of mixed mullerian tumours after tamoxifen therapy for breast cancer. J Natl Cancer Inst 96 (2004) 70-74
108. Mignotte H., Lasset C., Bonadona V., et al. Iatrogenic risks of endometrial cancer after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer 76 (1998) 325-330
109. Barakat R.R. The effect of tamoxifen on the endometrium. Oncology (Williston Park) 9 (1995) 129-134
110. Jordan V.C., and Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen?. Eur J Cancer A 30 (1994) 1714-1721
111. Magriples U., Naftolin F., Schwartz P.E., and Carcangiu M.L. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11 (1993) 485-490
112. Dallenbach-Hellweg G., and Hahn U. Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antioestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol 14 (1995) 7-15
113. Schlesinger C., Kamoi S., Ascher S., et al. Endometrial polyps: a comparison study of patients receiving tamoxifen within two control groups. Int J Gynecol Pathol 17 (1998) 302-311
114. Dallenbach-Hellweg G., Schmidt D., Hellberg P., et al. The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet 263 (2000) 170-177
115. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancer. J Natl Cancer Inst 92 (2000) 924-930
116. Chow L.M.L., and Baker S.J. PTEN function in normal and neoplastic growth. Cancer Lett 241 (2006) 184-196
117. Guzeloglu-Kayisli O., Kayisli U.A., Al-Rejjal R., et al. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab 88 (2003) 5017-5026
118. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 85 (2000) 2334-2338
119. Mutter G.L., Baak J.P.A., Fitzgerald J.T., et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 83 (2001) 177-185
120. Zheng W., Baker H.E., and Mutter G.L. Involution of PTEN-null endometrial glands with progestin therapy. Gynecol Oncol 92 (2004) 1008-1013
121. Kong D., Suzuki A., Zou T.T., et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17 (1997) 143-144
122. Risinger J.I., Hayes A.K., Berchuck A., and Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57 (1997) 4736-4738
123. Moreno-Bueno G., Sanchez-Estevez C., Cassia R., et al. Differential gene expression profile in endometrioid and non-endometrioid endometrial carcinoma STK15 is frequently overexpressed and amplified in non-endometrioid carcinomas. Cancer Res 63 (2003) 5697-5702
124. Risinger J.I., Berchuck A., Kohler M.F., et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53 (1993) 5100-5103
125. Maxwell G.L., Risinger J.I., Alvarez A.A., Barrett J.C., and Berchuck A. Microsatellite instability is associated with favourable survival in endometrial carcinomas. Obstet Gynecol 97 (2001) 417-422
126. Maxwell G.L., Risinger J.I., Hayes K.A., et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res 6 (2000) 2999-3005
127. Maxwell G.L., Chandramouli G.V., Dainty L., et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumours reveals distinct gene expression profiles associated with different histological subtypes of uterine cancer. Clin Cancer Res 11 (2005) 4056-4066
128. Peinado H., Marin F., Cubillo E., et al. Snail and E47 repressors of E-cadherin induce distinctly invasive and angiogenic properties in vivo. J Cell Sci 117 (2004) 2827-2839
129. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 94 (2004) 256-266
130. White I.N., de Matteis F., Davies A., et al. Genotoxic potential of tamoxifen and analogues in femal Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13 (1992) 2197-2203
131. Hemminki K., Rajaniemi H., Lindahl B., and Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56 (1996) 4374-4377
132. White I.N. The tamoxifen dilemma. Carcinogenesis 20 (1999) 1153-1160
133. Carmichael P.L. Mechanisms of action of antioestrogens: relevance to clinical benefits and risks. Cancer Invest 16 (1998) 604-611
134. White I.N. Anti-oestrogenic drugs and endometrial cancers. Toxicol Lett 120 (2001) 21-29
135. Shiau A.K., Barstad D., Loria P.M., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
136. Dardes R.C., Schafer J.M., Pearce S.T., et al. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 85 (2002) 498-506
137. Sakamoto T., Eguchi H., Omoto Y., et al. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol 192 (2002) 93-104
138. Wang Z., Kyo S., Maida Y., et al. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cells. Oncogene 21 (2002) 3517-3524
139. Watanabe T., Inoue S., Ogawa S., et al. Agonistic effect of tamoxifen is dependent on cell type ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors and α and β. Biochem Biophys Res Commun 236 (1997) 140-145
140. Jones P.S., Parrott E., and White I.N. Activation of transcription by estrogen by receptor α and β is cell type- and promoter-dependent. J Biol Chem 274 (1999) 32008-32014
141. Wu H., Chen Y., Liang J., et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438 (2005) 981-987